最新医学別冊　新しい診断と治療のABC25/内分泌2　甲状腺疾患　改訂第2版

出版社： 最新医学社
発行日： 2012-10-25
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： 甲状腺疾患　改訂第2版
電子書籍版： 2012-10-25 （改訂第2版）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC25/内分泌2　甲状腺疾患　改訂第2版

    ―目次―

    特集　甲状腺疾患　改訂第2版

    第1章　 概念・定義と疫学
    　甲状腺中毒症の定義・分類・疫学 　
    　甲状腺機能低下症の定義・分類・疫学　
    　甲状腺腫瘍の定義・分類・疫学

    第2章　病態生理・病理
    　甲状腺機能異常症の病因と病態生理　
    　甲状腺腫瘍の病因と病態生理 　
    　甲状腺疾患の病理と問題点

    第3章　鑑別診断
    　甲状腺機能異常症の臨床検査所見と鑑別診断 　
    　甲状腺ホルモン不応症の臨床検査所見と鑑別診断 　
    　新生児・小児甲状腺疾患の検査と鑑別診断　
    　甲状腺の画像診断と鑑別診断　
    　甲状腺腫瘍の穿刺吸引細胞診断

    第4章　診断・ 管理・治療
    　甲状腺クリーゼの診断と治療 　
    　バセドウ病眼症の診断と治療 　
    　バセドウ病の薬物療法 　
    　抗甲状腺薬の副作用と対策　
    　バセドウ病の131I内用療法・選択基準　
    　バセドウ病の外科治療
    　粘液水腫性昏睡の診断と治療　
    　甲状腺機能低下症の薬物療法　
    　妊娠出産時甲状腺能異常の治療　
    　甲状腺腫瘍の外科療法・選択基準　
    　甲状腺腫瘍の131I内用療法・薬物療法選択基準

    第5章　放射線障害と甲状腺疾患
    　放射線と甲状腺疾患-原爆被爆者の知見から-　
    　原発事故と甲状腺がん
    　放射線障害と甲状腺疾患：原子力事故と甲状腺ブロック

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義と疫学

P.25 掲載の参考文献
1) Braverman LUR:Introduction to thyrotoxicosis. In:The Thyroid, p515-517. Rippincott-Raven, Philladelphia, 2005.
 
2) Refetoff S, et al:The syndromes of resistance to thyroid hormone. Endocr Rev 14:348-399, 1993.
PubMed
3) Bochukova E, et al:A mutation in the thyroid hormone receptor alpha gene. N Engl J Med 366:243-249, 2012.
 
4) Rodien P, et al:Abnormal stimulation of the thyrotrophin receptor during gestation. Hum Reprod Update 10:95-105, 2004.
PubMed
5) Hamburger JI:The autonomously functioning thyroid nodule:Goetsch's disease. Endocr Rev 8:439-447, 1987.
 
6) Parma J, et al:Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-651, 1993.
PubMed
7) Parma J, et al:Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 82:2695-2701, 1997.
PubMed
8) Spiegel A M, et al:Receptor-effector coupling by G proteins:implications for normal and abnormal signal transduction. Endocr Rev 13:536-565, 1992.
PubMed
9) Cakir M:Diagnosis of Marine-Lenhart syndrome. Thyroid 14:555, 2004.
PubMed
10) Duprez L, et al:Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 7:396-401, 1994.
PubMed
11) Amino N, et al:High prevalence of transient post-partum thyrotoxicosis and hypothyroidism. N Engl J Med 306:849-852, 1982.
PubMed
12) Shigemasa C, et al:Chronic thyroiditis with painful tender thyroid enlargement and transient thyrotoxicosis. J CLin Endocrinol Metab 70:385-390, 1990.
PubMed
13) Hedberg CW, et al:An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 316:993-998, 1987.
PubMed
14) Brown W W, et al:Hyperthyroidism due to struma ovarii:demonstration by radioiodine scan. Acta Endocrinol 73:266-272, 1973.
PubMed
15) Bogazzi F, et al:Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 95:2529-2535, 2010.
 
16) Vadiveloo T, et al:The Thyroid Epidemiology, Audit, and Research Study (TEARS):morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 96:1344-1351, 2011.
PubMed
17) Collet T H, et al:Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 172:799-809, 2012.
PubMed
18) Lee JS, et al:Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 170:1876-1883, 2010.
PubMed
19) Cooper D S, et al:Subclinical thyroid disease. Lancet 379:1142-1154, 2012.
PubMed
20) Perissi V, et al:Deconstructing repression:evolving models of corepressor action. Nat Rev Genet 11:109-123, 2010.
PubMed
21) Davis PJ, et al:Membrane receptor for thyroid hormone:physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 51:99-115, 2011.
PubMed
22) Yamada M, et al:Mechanisms related to the pathophysiology and management of central hypothyroidism. Natl Clin Pract Endocrinol Metab 4:683-694, 2008.
 
23) Visser WE, et al:Thyroid hormone transporters:the knowns and the unknowns. Mol Endocrinol 25:1-14, 2011.
PubMed
24) Williams GR, et al:Deiodinases:the balance of thyroid hormone:local control of thyroid hormone action:role of type 2 deiodinase. J Endocrinol 209:261-272, 2011.
PubMed
P.33 掲載の参考文献
1) Dumitrescu AM, et al:Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Natl Genet 37:1247-1252, 2005.
 
2) Cosmo CD, et al:Clinical and molecular characterization of a novel selenocystein insertion sequence-binding protein 2 gene mutation. J Clin Endocrinol Metab 94:4003-4009, 2009.
 
3) Heuer H, et al:The monocarboxylate transporter linked to human psychomotor retardation is highly expressed in thyroid hormone-sensitive neuron populations. Endocrinology 146:1701-1706, 2005.
PubMed
4) Huang SA, et al:Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 343:185-189, 2000.
PubMed
5) WBrent G A, et al:Hypothyroidism and thyroiditis. In:Williams Textbook of Endocrinology 12th ed, p406-407. Saunders, Philadelphia, 2011.
 
6) Vanderpump M P J:The epidemiology of thyroid diseases. In:Werner and Ingbar's The Thyroid 9th ed, p400-401. 2005.
 
7) 猪俣弘明:先天性甲状腺機能低下症の診断と治療. よくわかる甲状腺疾患のすべて 改定第二版 (伴 良雄編) p265. 永井書店, 大阪 2009.
 
8) 網野信行:「Subclinical hypothyroidism 潜在性甲状腺機能低下症の実態調査と治療手引き」作成までの経緯. ホルモンと臨 653, 2008.
 
9) あすか製薬 (株):私信
 
P.42 掲載の参考文献
1) Higashiyama T, et al:Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma Thyroid 20 (1):7-14, 2010.
PubMed
2) Miyauchi A, et al:Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma Ann Surg 199 (4):461-466, 1984.
PubMed
3) 浜田 昇:甲状腺疾患発見の手がかり-何をもって疑うか. 内科 100:814-819, 2007.
 
4) 竹内 功, 他:当施設における甲状腺検診. 外科診療 33:578-582, 1991.
 
5) Miki H, et al:Value of mass screening for thyroid cancer. World J Surg 22 (1):99-102, 199&
 
6) 志村浩巳:甲状腺腫瘍の疫学 (日本人における偶発腫瘍発見率, 罹患率, risk factor, 予後). 甲状腺腫瘍へのアプローチ 29:179-185, 2009.
 
7) 貴田岡正史:甲状腺疾患の超音波診断. よく分かる甲状腺疾患のすべて (伴 良雄編), p91-102, 永井書店, 2009.
 
8) 武部晃司, 他:甲状腺超音波検診で発見される甲状腺微小癌の問題点 (innocent carcinomaの問題点). 内分泌外科 14 (3):181-184, 1997.
 
9) 高田憲次, 他:当院の人間ドックにおける甲状腺超音波検査の現状について. 健康医 7:38-41, 1992.
 
10) Yamamoto Y, et al:Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer 65 (5):1173-1179, 1990.
PubMed
11) 人口動態統計 (厚生労働省大臣官房統計情報部 編)
 
12) 岩崎博幸, 他:甲状腺癌の疫学に関する最新のデータ. 臨外 62:39-46, 2007.
 
13) Thompson DE, et al:Cancer incidence in atomic bomb survivors. Part II:Solid tumors, 1958-1987. Radiat Res 137 (2 Suppl):S17-S67, 1994.
 
14) Imaizumi M, et al:Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. JAMA 295 (9):1011-1022, 2006.
PubMed

第2章 病態生理・病理

P.49 掲載の参考文献
1) 菱沼 昭:日常診療における遺伝子異常:どの様な患者で遺伝子異常診断を施行すべきか? 日甲状腺会誌 2 (1):22-25, 2011.
 
2) Mao C, et al:Impairment of regulatory capacity of CD4+CD25+regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves's disease. J Immunol 186 (8):4734-4743, 2011.
 
3) Figueroa-Vega N, et al:Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. J Clin Endocrinol Metab 95 (2):953-962, 2012.
 
4) Zhu C, et al:Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J Clin Endocrinol Metab 97 (3):943-950, 2011.
PubMed
5) Tomer Y, et al:The etiology of autoimmune thyroid disease:astory of genes and environment. J Autoimmun 32 (3-4):231-239, 2009.
 
6) Colobran R, et al:Association of an SNP with intrathymic transcription of TSHR and Graves' disease:a role for defective thymic tolerance. Hum Mol Genet 20 (17):3415-3423, 2011.
PubMed
7) Nagayama Y, et al:A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 168 (6):2789-2794, 2002.
PubMed
8) Kaneda T, et al:An improved Graves:disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice. Endocrinology 148 (5):2335-2344, 2007.
PubMed
9) Nakahara M, et al:Adoptive transfer of antithyrotropin receptor (TSHR) autoimmunity from TSHR knockout mice to athymic nude mice. Endocrinology 153 (4):2034-2042, 2012.
PubMed
10) Zhao S X, et al:Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol 210 (3):369-377, 2011.
 
P.57 掲載の参考文献
1) 志村浩己:日本における甲状腺腫瘍の頻度と経過-人間ドッグからのデータ. 日本甲状腺学会雑誌 1 (2):109-113, 2010.
 
2) Kondo T, et al:Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6 (4):292-306, 2006.
PubMed
3) Takano, T:Fetal cell carcinogenesis of the thyroid:theory and practice. Semin Cancer Biol 17 (3):233-240, 2007.
PubMed
4) Lin RY:Thyroid cancer stem cell Nat Rev Endocrinol 7 (10):609-616, 2011.
PubMed
5) Todaro M, et al:Tumorigenic and metastastic activity of human thyroid cancer stem cells. Cancer Res 70 (21):8874-8885, 2010.
 
6) Trueba S S, et al:PAX8, TITF1, and FOXE1 gene expression patterns during human development:new insights into human thyroid development and thyroid dysgenesis-associated malformations. J Clin Endocrinol Metab 90 (1):455-462, 2005.
PubMed
7) Rubio D, et al:Spontaneous human adult stem cell transformation. Cancer Res 65 (8):3035-3039, 2005.
PubMed
P.67 掲載の参考文献
1) DeLellis R A, et al:Tumours of Endocrine Organs, World Health Organization Classification of Tumours; Pathology and Genetics, IARC Press, Lyon, 2004.
 
2) 日本甲状腺外科研究会 編:甲状腺癌取り扱い規約. 金原出版, 東京, 2005.
 
3) The Papanicolaou society of cytopathology. Guidelines of the Papanicolaou society of cytopathology for the examination of fine-needle aspiration specimens from thyroid nodules. Diagn Cytoplathol 15:84-89, 1996.
PubMed
4) 越川 卓, 他:甲状腺濾胞性腫瘍の細胞診断における問題点-新しい報告様式の提唱-. 日臨細胞会誌 41:360-367, 2002.
 
5) 越川 卓, 他:甲状腺細胞診のガイドライン:新しい報告様式. 病理と臨 23:33-38, 2005.
Medical*Online
6) 覚道健一, 他:濾胞性腫瘍の細胞診断ガイドライン作成に向けて. 日臨細胞会誌 49:37-41, 2010.
 
7) 藤澤俊道, 他:甲状腺濾胞性腫瘍の診断基準と診断精度-伊藤病院での検討-. 日臨細胞会誌 49:42-47, 2010.
 
8) 前川観世子, 他:甲状腺濾胞性腫瘍の細胞診-診断の現状と細胞学的鑑別-. 日臨細胞会誌 49:48-54, 2010.
 
9) 丸田淳子, 他:甲状腺穿刺細胞診-濾胞性腫瘍の取り扱い-. 日臨細胞会誌 49:55-60, 2010.
 
10) 谷口恵美子, 他:「良悪鑑別困難」の細分類-腺腫結節の細胞所見と濾胞性腫瘍の細胞所見-. 日臨細胞会誌 49:61-66, 2010.
 
11) 日本甲状腺学会編:甲状腺結節取り扱い診療ガイドライン, 南江堂 (出版準備中)
 
12) Ali SZ, et al:The Bethesda system for reporting thyroid cytopathology. Definitions, criteria and explanatory notes. Springer, New York, 2010.
 
13) Volante M, et al:Poorly differentiated thyroid carcinoma:the Turine proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31:1256-1264, 2007.
 
14) Ito Y, et al:Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg 32:1535-1543, 2008.
PubMed
15) Kakudo K, et al:Classification of thyroid follicular cell tumors:with special reference to borderline lesions. Endocr J 59:1-12, 2012.
PubMed
16) Renshaw AA:Focal features of papillary carcinoma of the thyroid in fine-needle aspiration material are strongly associated with papillary carcilloma at resection. Am J Clin Pathol 118:208-210, 2002.
PubMed
17) Weber D, et al:A typical epithelial cells, cannot exclude papillary Carcinoma, in fine needle aspiration of the thyroid. Acta Cytol 52:320-324, 2008.
 
18) Sahin M, et al:Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules. Clin Endocrinol (Oxf) 65:514-518, 2006.
PubMed
19) Alexander EK:Approach to the patient with a cytologically indeterminate thyroid nodule. J Clin Endocrinol Metab 93:4175-4182, 2008.
 

第3章 鑑別診断

P.76 掲載の参考文献
1) Hollowell JG, et al:Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994):National Health and Nutrition Examination Survey (NHANES HI). J Clin Endocrinol Metab 87 (2):489-499, 2002.
 
2) Surks MI, et al:Age-specific distribution of serum thyrotropin and antithyroid anti-bodies in the U.S. population:Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 92 (12):4575-4582, 2007.
 
3) Boucai L, et al:An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid 21 (1):5-11, 2011.
PubMed
4) Arnaud-Lopez L, et al:Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. Am J Hum Genet 82 (6):1270-1280, 2008.
PubMed
5) Shields B M, et al:Phosphodiesterase 8B gene polymorphism is associated with sub-clinical hypothyroidism in pregnancy. J Clin Endocrinol Metab 94 (11):4608-4612, 2009.
 
6) Panicker V, et al:Alocus on chromosome 1p36 is associated with thyrotropin and thyroid function as identified by genome wide association study, Am J Hum Genet 87 (3):430-435, 2010.
 
7) Andersen S, et al:Narrow individual variations in serum T4 and T3 in normal subjects:A clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 87 (3):1068-1072, 2002.
 
8) Andersen S, et al:Biologic variation is important for interpretation of thyroid function tests. Thyroid 13 (11):1069-1078, 2003.
PubMed
9) 平成23年度第45回臨床検査精度管理調査結果報告書, 日本医師会 http://www.jmaqc.jp/sv/report/index.php
 
10) Thienpont LM, et al:Report of the IFCC working group for standardization of thyroid function tests; Part 1:thyroid-stimulation hormone. Clin Chem 56 (6):902-911, 2010.
 
11) Thienpont LM, et al:Report of the IFCC working group for standardization of thyroid function tests; Part 1:thyroid-stimulation hormone. Clin Chem 56 (6):902-911, 2010.
 
12) Nishihara E, et al:Subclinical nonautoimmune hyperthyroidism in a family segregates with a thyrotropin receptor mutationwith weakly increased constitutive activity. Thyroid 20 (11):1-8, 2010.
 
13) 西原永潤, 他:TRAb陰性のびまん性甲状腺機能亢進症84例における, TSH受容体胚細胞変異頻度と臨床経過. 日内分泌会誌 88 (1):250, 2012.
Medical*Online
14) Hishinuma A, et al:Haplotype analysis reveals founder effects of thyroglobulin genemutations C1058S and C1977S in Japan. J Clin Endocrinol Metab 91 (8):3100-3104, 2006.
 
15) Ohye H, et al:A novel homozygous missense mutation of the Dual 0xidase 2 (DUOX2) gene in an adult patient withlarge goiter. Thyroid 18 (5):561-566, 2008.
 
16) Shibayama K, et al:Subclinical hypothyroidism caused by a mutation of the thyrotropin receptor gene. Pediatrics Int 47:105-108, 2005.
PubMed
17) Tsunekawa K, et al:Identification and functional analysis of novel inactivating thyrotropin receptor mutations in patientswith thyrotropin resistance. Thyroid 16 (5):471-479, 2006.
 
18) 深田修司, 他:成人の軽度～潜在性非自己免疫性甲状腺機能低下症におけるTSH受容体(TSHR)遺伝子の変異の有無・頻度の検討. 日内分泌会誌 88 (1):323, 2012.
Medical*Online
19) Bochukova E, et al:A mutation in the thyroid hormone receptor alpha gene. N Engl J Med 366 (3):243-249, 2012.
 
20) Kanou Y, et al:Thyroglobulin gene mutations producing defective intracellular transport of thyroglobulin are associated with increased thyroidal type 2 iodothyronine deiodinase activity. J Clin Endocrinol Metab 92 (4):1451-1457, 2007.
PubMed
21) Hamajima T, et al:Novel compound heterozygous mutations in the SBP2 gene:characteristic clinical manifestations and the implications of GH and triiodothyronine in longitudinal bone growth and maturation. Eur J Endocrinol 166:757-764, 2012.
PubMed
22) 溝田美智代, 他:Monocarboxylate transporter 8 (MCT8) 遺伝子変異を認めた2例. 日甲状腺学会誌 1 (2):126-128, 2010.
 
P.88 掲載の参考文献
1) Refetoff S, et al:Familial syndrome combining deaf-mutism, stippled epiphyses, goiter, and abnormally high PBI:possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab 27:279-294, 1967.
PubMed
2) Refetoff S:Resistance to thyroid hormone. In:Werner and Ingbar's the Thyroid, 9th ed (Breverman LaU, RD ed). pp1109-1129. Williams & Wilkins, Philadelphia, 2005.
 
3) Bochukova E, et al:A Mutation in the Thyroid Hormone Receptor Alpha Gene. N Engl J Med 366:243-249, 2012.
 
4) Sakurai A, et al:Generalized resistance to thyroid hormone associated with a mutation in the ligand binding domain of human thyroid hormone receptor B. Proc Natl Acad Sci 86:8977-8981, 1989.
 
5) Dumitresu AM, et al:Chapter 58 Reduced sensitivity to thyroid hormone:Defects of transport metabolism, and action. In:Werner and Ingbar's the Thyroid, 10th ed (Breverman LaU, RD ed). pp845-873. Williams & Wilkins, Philadelphia (in press)
 
6) Refetoff S, et al:Syndromes of reduced sensitivity to thyroid hormone:genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Clin Endocrinol Metab 21:277-305, 2007.
PubMed
7) Sakurai A, et al:Dominant negative transcriptional regulation by a mutant thyroid hormone receptor-B in a family with generalized resistance to thyroid hormone. Mol Endocrinol 4:1988-1994, 1990.
 
8) Ono S, et al:Homozygosity for a "dominantnegative" thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. J Clin Endocrinol Metab 73:990-994, 1991.
 
9) Ferrara AM,et al:Homozygous thyroid hormone receptor beta-gene mutations in resistance to thyroid hormone:three new cases and review of the literature.J Clin Endocrinol Metab 97:1328-1336,2012.
PubMed
10) Sadow P, et al:Resistance to thyroid hormone in the absence of mutations in the thyroid hormone receptor genes. Curr Opin Endocrinol Diabetes 7:253-259, 2000.
 
11) Gershengorn MC, et al:Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of "inappropriate secretion of TSH". J Clin Invest 56:633-642, 1975.
PubMed
12) Beck-Peccoz P, et al:Pituitary tumours:TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 23:597-606, 2009.
PubMed
13) Beck-Peccoz P, et al:Thyrotropin-secreting pituitary tumors. Endocr Rev 17 (6):610-638, 1996.
PubMed
14) Hall WA, et al:Pituitary magnetic resonance imaging in normal human volunteers:occult adenomas in the general population. Ann Intern Med 120:817-820, 1994.
PubMed
P.108 掲載の参考文献
1) 小児基準値研究班編:日本人小児の臨床検査基準値. 日本公衆衛生協会出版, 東京, 1996.
 
2) クレチン症マススクリーニング・ガイドライン作成委員会:先天性甲状腺機能低下症マススクリーニングのガイドライン (1998年版). 日小児科会誌 102:817-819, 1998.
 
3) De Felice M, et al:Thyroid development and its disorders:genetics and molecular mechanism. Endocr Rev 25:722-746, 2004.
PubMed
4) Jameson J L, et al:Disorders of the thyroid gland. In:Harrison:s Endocrinology (Jameson J L, ed). p71-112. McGraw-Hill, Chicago, 2006.
 
5) Rapaport R, et al:Hypothyroxinemia in the preterm infant:The benefits and risks of thyroxine treatment. J pediatr 136:182-188, 2001.
 
6) 河井昌彦, 他:早産児の低サイロキシン血症に対する補充用法前後での甲状腺機能の変化に関する検討. 日周産期新生児会誌 44:1192-1196, 2008.
 
7) McKenzie J M, et al:Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 2:155-159, 1992.
PubMed
8) Matsuura N, et al:The mechanism of transient hypothyroxinemia in infants born to mothers with Graves' disease. Pediatr Res 42:214-218, 1997.
PubMed
9) LaFranch S:Hyperthyroidism. In:Nelson Textbook of Pediatrics. 17th ed (Behrman R E, et al, eds). pp1884-1887, Saunders, Philaderphia, 2004.
 
10) 小児期発症バセドウ病薬物治療のガイドライン 2008. 日小児科会誌 112:946-952, 2008.
 
11) Refetoff S, et al:Syndromes of reduced sensitivity to thyroid hormone:genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Clin Endocrinol Metab 21:277-305, 2007.
PubMed
12) Thyroid disease manager (http://www.thyroidmanager.org/)
 
13) Cooper D S, et al:The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142, 2006.
PubMed
P.121 掲載の参考文献
1) 三谷康二:甲状腺エコー検査の最近の進歩. Med Pract 28 (11):1965-1971, 2011.
Medical*Online
2) 貴田岡正史:甲状腺疾患の診断と治療のポイント 甲状腺疾患の超音波診断. 内科 80 (5):851-856, 1997.
 
3) 日本乳腺甲状腺超音波診断会議 編:甲状腺超音波診断ガイドブック改訂第2版. 南江堂, 東京, 2012.
 
4) 鈴木眞一:超音波の最新技術-エラストグラフィ. 医のあゆみ 239 (2):149-153, 2011.
Medical*Online
5) 南本亮吾:集積パターンと併用検査に基づくFDG-PETがん検診の要精査判定方法. 核医 46 (2):73-93, 2009.
Medical*Online
P.135 掲載の参考文献
1) 鳥屋城男:甲状腺結節の細胞診による診断と限界. KARKINOS 6:383-389, 1993.
 
2) 福成信博:エコーガイド下穿刺吸引細胞診. 甲状腺疾患診療実践マニュアル第3版 (三村 孝, 他 編), p210-212. 文光堂, 東京, 2007.
 
3) 小野田教高, 他:穿刺吸引細胞診:実施と診断. 甲状腺疾患診療マニュアル (田上哲也, 他 編, p45-47. 診断と治療社, 東京, 2009.
 
4) Yokozawa T, et al:Accurate and simple method of diagnosing thyroid nodules by the modified technique of ultrasound-guided fine needle aspiration biopsy. Thyroid 5:141-145, 1995.
PubMed
5) Polyzos S A, et al:Clinical complications following thyroid fine-needle biopsy:a systematic review. Clin Endocrinol 71:157-165, 2009.
PubMed
6) 甲状腺外科研究会編:甲状腺癌取扱い規約第6版, 金原出版株式会社, 東京, 2005.
 
7) All SZ, et al:甲状腺細胞診ベセスダシステム (坂本穆彦 監訳), シュプリンガー・ジャパン社, 東京, 2011.
 
8) 北川 亘, 他:内分泌腺腫瘍 穿刺吸引細胞診検査. 日臨 69 (Suppl):320-323, 2011.
 
9) 越川 卓, 他:甲状腺細胞診のガイドライン:新しい報告様式. 病理と臨 23:33-38, 2005.
Medical*Online
10) 土屋眞一, 他:穿刺吸引細胞診の新しい報告様式-乳腺と甲状腺-. 病理と臨 23:642-646, 2005.
Medical*Online
11) 越川 卓:甲状腺細胞診の新しい報告様式:その診断成績および実用の手引き. 診断病理 22:73-79, 2005.
Medical*Online
12) 藤澤俊道, 他:甲状腺濾胞性腫瘍の診断基準と診断精度-伊藤病院での検討-. 日臨細胞誌 49:42-47, 2010.
Medical*Online

第4章 診断・管理・治療

P.141 掲載の参考文献
1) Tietgens S T, et al:Thyroid storm. Med Clin North Am 79:169-184, 1995.
PubMed
2) Akamizu T, et al:Diagnostic criteria clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 22:661-679, 2012.
PubMed
3) 赤水尚史, 他:甲状腺クリーゼ. 内科 107:115-118, 2011.
 
4) 赤水尚史:甲状腺クリーゼの新たな診断基準の作成. クリニカルアワー「甲状腺クリーゼの診断基準と実際」第80回日本内分泌学会学術総会抄録集 p85. 2007.
 
5) 赤水尚史, 他:甲状腺クリーゼ診断基準 (第2版). (http://www.japanthyroid.jp/doctor/problem.html.2012.)
 
6) 赤水尚史, 他:甲状腺クリーゼ診断基準 (第2版). (http://square.umin.ac.jp/endocrine/rinsho_juyo/index.html.2012:)
 
7) 赤水尚史:甲状腺クリーゼの診断基準と全国疫学調査. ホルモンと臨 58:641-649, 2010.
 
8) 赤水尚史:甲状腺クリーゼ. In:内分泌代謝専門医ガイドブック 改訂第2版 (成瀬光栄, 他編). p148-151. 診断と治療社, 東京, 2009.
 
P.150 掲載の参考文献
1) Bahn R S:Graves' ophthalmopathy. N Engl J Med 362:726-738, 2010.
PubMed
2) Bartalena L, et al:Management of Graves:ophthalmopathy:reality and perspectives. Endocr Rev 21:168-199, 2000
PubMed
3) Werner S C:Modification of the classification of the eye changes of Graves' disease:recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 44:203-204, 1997.
 
4) 廣松雄治:Basedow 病眼症. 日内会誌 99:755-762, 2010.
 
5) Douglas RS, et al:Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 95:438, 2010.
 
6) Bartalena L, et al:Consensus statement of the European Group on Graves:orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273-285, 2008.
 
7) Hiromatsu Y, et al:role of magnetic resonance imaging in thyroid-associated ophthalmopathy:its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 2:299-305, 1992.
PubMed
8) 三村 治, 他:バセドウ病眼症に対する薬剤局所投与と外眼筋手術. 内分泌糖尿病代謝内科 31:158-165, 2010.
 
9) 坪内博仁, 他:免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告-. 肝臓 50:38-42, 2009.
 
10) Salvi M, et al:Treatment of Graves:disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab:an open study. Eur J Endocrinol 156:33-40, 2007.
PubMed
P.162 掲載の参考文献
1) 日本甲状腺学会編:バセドウ病薬物治療のガイドライン 2006. 南江堂, 東京, 2006.
 
2) 日本甲状腺学会編:バセドウ病治療ガイドライン 2011. 南江堂, 東京, 2011.
 
3) Nakamura H, et al:Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 92:2157-2162, 2007.
PubMed
4) Bahn R S, et al:Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593-6646, 2011.
 
5) Abraham P, et al:A systematic review of drug therapy for Graves:hyperthyroidism. Eur J Endocrinol 153:489-498, 2005.
 
6) Takata K et al:Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19:559-563, 2009.
 
7) Nakamura H:(in preparation)
 
8) 中村浩淑:バセドウ病の薬物治療. 日甲状腺誌 1:15-18, 2010.
 
9) Allannic H, et al:Antithyriod drugs and Graves' disease:a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 70:675-679, 1990.
 
10) Feldt-Rasmussen U, et al:Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 78:98-102, 1994.
PubMed
11) Di Gianantonio E, et al:Adverse effects of prenatal methimazole exposure. Teratology 64:262-266, 2001.
PubMed
12) 中村浩淑, 荒田尚子:妊娠初期のチアマゾール投与に関する注意喚起について (2011. 11. 30) (http://www.japanthyroid.jp/doctor/information/index.html#ninshin)
 
P.173 掲載の参考文献
1) Nakamura H, et al:Comparison of methimazole and propylthiouracil in patients with hyperthyroidism with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metan 92:2157-2162, 2007.
 
2) Rivkees S A:The treatment of Graves' disease in children. J Pediat End Metab 19:1095-1111, 2006.
 
3) Tajiri J, et al:Antithyroid drug-inducedagranulocytosis:special reference to normal white blood cell cunt agranulocytosis. Thyroid 14:459-462, 2004.
 
4) Tajiri J, et al:Antithyroid drug-inducedagranulocytosis:How has granulocyte colony-stimulating factor changed therapy? Thyroid 15:292-297, 2005.
PubMed
5) Takata K, et al:Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose od 30mg daily than with 15mg daily 19:559-563, 2009.
 
6) 医薬品医療機器総合機構(PMDA)副作用が疑われる症例報告に関する情報 http://www.info.pmda.go.jp/fukusayou/menu_fukusayou_attention.html
 
7) Kim H-J, et al:The incidence and clinical characteristics of symptomatic Propylthiouracil-induced hepatic injury in patients with hyperthyroidism:a single-center retrospective study. Am J Gastroent 96:165-169, 2001.
PubMed
8) 2008 Hepatic toxicity following treatmentin pediatiric Graves' disease. Minutes of October 28, 2008 meeting. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Http://bpca.nichd.nih.gov/outreach/index.cfm#08
 
9) Rivkees S A, et al:Propylthiouracil (PTU) hepatotoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 10. 1155/2009/132041
 
10) Rivkees S A, et al:Ending propylthiouracil induced liver failure in children. N Engl J Med 360:1574-1575, 2009.
PubMed
11) Cooper D S, et al:Putting Propylthiouracilin perspective. J Clin Endocrinol Metab 94:1881-1882, 2009.
PubMed
12) Morris C V, et al:An unsual presentationof fulminant hepatic failure secondary topropylthiouracil therapy. Clinical Transplants 311, 1989.
 
13) Ruiz J K et al:Fulminant hepatic failureassociated with Propylthiouracil. Ann Pharmacother 37:224-228, 2003.
 
14) Yoshimura J N, et al:Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculaitis causedby antithyroid drugs. J Clin Endorinol Metab 94:2806-2811, 2009.
 
15) Diazzi C, et al:Propylthiouracil-induced interstitial pneumonia in a Caucasian woman with amiodarone-induced thyrotoxicosis. Thyroid 22:325-329, 2012.
 
16) Shabtai R, et al:The antithyroid arthritis syndrome reviewed. Arth Rheum 27:227-229, 1984.
 
17) 日本甲状腺学会編:バセドウ病治療ガイドライン 2011, 南江堂, 東京, 2011.
 
18) FDA Drug Safety Communication:New Boxed Warning on severe liver injury with propylthiouracil (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/ucm209023.htm)
 
19) 上條桂一, 他:抗甲状腺薬の安全対策-無顆粒球症の対応について. Pharm Medica 24:65-71, 2006.
Medical*Online
20) Chen B, et al:Recurrent agranulocytosis induced by two different antithyroid agents. Med J Aust 2:38-39, 1983.
PubMed
P.178 掲載の参考文献
1) Tominaga T, et al:International differences in approaches to 131I therapy for Graves' disease:Case selection and restrictions recommended to patients in Japan, Korea, and China. Thyroid 7 (2):217-220, 1997.
PubMed
2) Saenger E L, et al:Incidence of leukemia following treatment of hyperthyroidism:Preliminary report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. JAMA 205 (12):855-862, 196&
 
3) Ron E, et al:Cancer mortality following treatment for adult hyperthyroidism:Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280 (4):347-355, 1998.
PubMed
4) 日本甲状腺学会:131I 内用療法:131I 投与量の決め方. バセドウ病治療ガイドライン 2011. p194-203, 南江堂, 東京, 2011.
 
5) 三枝健二:甲状腺機能亢進症患者 131I 治療量投与後の経時的全身計測と吸収線量の評価. 日医放射線会誌 34:404-415, 1974.
 
6) Graham G D, et al:Radioiodine treatment of Graves' disease:An assessment of its potential risks. Ann Intern Med 105 (6):900-905, 1986.
PubMed
7) Hayek A, et al:Long-term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine. N Engl J Med 283:949-953, 1970.
PubMed
8) Casara D, et al:Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer:Potential risks and recommendations. Eur J Nucl Med 20:192-194, 1993.
PubMed
9) Schlumberger M, et al:Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606-612, 1996.
 
10) 日本甲状腺学会:131I 内用療法:治療後, 妊娠を控える期間について. バセドウ病治療ガイドライン 2011. p170-174, 南江堂, 東京, 2011.
 
11) Meier D A, et al:Society of Nuclear Medicine:Procedure guideline for therapy of thyroid disease with 131iodine. J Nucl Med 43 (6):856-861, 2002.
PubMed
12) International Commission on Radiation Protection:Pregnancy in medical radiation. ICRP Publication 84, Ann ICRP, 30, No. 1, 2001.
 
13) Nakajo M, et al:Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy. Ann Nucl Med 19 (4):297-308, 2005.
 
14) Hamada N, et al:Persistent high TRAb values during pregnancy predict increased risk of neonatal hyperthyroidism following radioiodine therapy for refractory hyperthyroidism. Endocr J 58 (1):55-58, 2011.
PubMed
15) 田尻淳一:RI治療後の妊娠における新生児バセドウ病とTRAb. 日内分泌会誌 81 (1):113, 2005.
 
16) Mykola D, et al:Thyroid carcinoma in children and adolescents in Ukraine after the Chernobyl nuclear accident Cancer 86 (1):149-156, 1999.
 
17) Rivkees S A, et al:The management of Graves' disease in children, with specialemphasis on radioiodine treatment. J Clin Endocrinol Metab 83:3767-3776, 1998.
PubMed
18) Reed C H Jr, et al:36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 89:4229-4233, 2004.
 
19) Tallstedt L, et al:Occurrence of ophthalmopathy after treatment of Graves:hyperthyroidism. N Engl J Med 326:1733-1738, 1992.
PubMed
20) Perros P, et al:A prospective study of the effect of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 90:5321-5323, 2005.
PubMed
P.188 掲載の参考文献
1) Tallstedt L et al:Ocurrence of opthal mopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326 (26):1733-1738, 1992.
 
2) 内野眞也:内分泌外科におけるインフォームド・コンセント (IC) のための説明文書. バセドウ病手術. 内分泌外科 18 (4):234-235, 2001.
 
3) 榎本敬恵, 他:バセドウ病の手術適応と術前管理. 内分泌糖尿病代謝内科 31 (2):177-182, 2010.
 
4) Dralle H:バセドウ病手術の歴史. 内分泌外科 11 (4):363-368, 1994.
 
5) 内野眞也, 他:小切開下の Basedow 病手術. 手術 59 (7):959-964, 2005.
 
6) 栗原英夫:甲状腺超亜全摘・全摘術. 内分泌外科の要点と盲点第2版 (幕内雅敏 監, 小原孝男 編), p108-112. 文光堂, 東京, 2007.
 
7) Alsanea O, et al:Treatment of Graves:disease:the advantages of surgery. Endocrinol Metab Clin North Am 29 (2):321-337, 2000
PubMed
8) Takamura Y, et al:Changes in serum TSH receptor antibody (TRAb) values in patients with Graves' disease after total or subtotal thyroidectomy. Endocr J 50 (5):595-601, 2003.
PubMed
9) 村上信夫, 他:小児のバセドウ病. 内分泌外科 4 (3):287-291, 1987.
 
10) Goto A, et al:NIS mRNA expression level in resected thyroid tissue as a marker of postoperative hypothyroidism after subtotal thyroidectomy in patients with Graves' disease. Endocr J 55 (1):73-81, 200&
 
P.198 掲載の参考文献
1) 日本甲状腺学会:臨床重要課題「粘液水腫性昏睡の診断基準と治療指針」作成委員会. 笠井貴久男, 2008.7～
 
2) 田中祐司:粘液水腫性昏睡の診断と治療. 甲状腺疾患診療マニュアル, p89-90. 診断と治療社, 東京, 2009.
 
3) Dutta P, et al:Predictors of outcome in myxedema coma:a study from a tertiary care centre. Critical Care 12:R1, 2008.
 
4) Rodriguez I, et al:Factors associated with mortality of patients with myxedema coma:prospective study in ll cases treated in a single institution J Endocrinol 180:347-350, 2004.
 
5) 小西美絵乃:粘液水腫性昏睡. 日内会誌 99:769-775, 2010.
 
6) 笠井貴久男:粘液水腫性昏睡の診断と治療-新しいガイドラインを踏まえて. Med Pract 28 (11):1977-1980, 2011.
Medical*Online
7) 松下明生:甲状腺機能亢進症・甲状腺クリーゼ/甲状腺機能低下症・粘膜水腫性昏睡. 救急・集中治療 18(7・8):1081-1084, 2006.
 
8) 柳一徳:粘液水腫性昏睡. Mod Physician 31(4):460-462, 2011.
 
9) Yamamoto T, et al:Factors associated with mortality of myxedema coma. Thyroid 9:1167-1174, 1999.
PubMed
P.206 掲載の参考文献
1) Dosiou C, et al:Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. J Clin Endocrinol Metab 97 (5):1536-1546, 2012.
PubMed
2) Fugazzola L, et al:Microchimerism and endocrine disorders. J Clin Endocrinol Metab 97 (5):1452-1461, 2012.
PubMed
3) 伊藤光泰:多腺性内分泌不全症 (PGA) の病因・病態と治療. 医のあゆみ 213 (5):439-444, 2005,
Medical*Online
4) 伊藤光泰:サブクリニカル甲状腺機能低下症における治療効果の評価. 内分泌糖尿病代謝内科 30 (5):421-427, 2010.
 
5) 伊藤光泰:潜在性甲状腺機能低下症. カレントテラピー 27 (2):73-77, 2009.
 
6) Ochs N, et al:Meta-analysis:subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 148:832-845, 2008.
PubMed
7) Rodondi N, et al:Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304:1365-1374, 2010.
PubMed
8) Razvi S, et al:The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism:Reanalysis of the Whickham Survey Cohort. J Clin Endocrinol Metab 95 (4):1734-174 2010.
PubMed
9) Nanchen D, et al:Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 97 (3):852-861, 2012.
PubMed
10) Marfella R, et al:Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab 96 (4):1015-1020, 2011.
PubMed
11) Asvold B O, et al:Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism:11-year follow-up of the HUNT study in Norway. J Clin Endocriol Metab 97 (1):93-99, 2012.
 
12) Walsh J p, et al:Thyrotropin and thyroid antibodies as predictors of hypothyroidism:A 13-year, longitudinal study of a community-based cohort using current immunoassay techniques. J Clin Endocrinol Metab 95 (3):1095-1104, 2010.
PubMed
13) Checchi S, et al:L-thyroxine requirementin patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab 93 (2):465-469, 2008.
 
14) Correia N, et al:Evidence for a specific defect in hippocampal memory in overt and subclinical hypothyroidism. J Clin Endocrinol Metab 94 (10):3789-3797, 2009.
PubMed
15) Bauer M, et al:Brain glucose metabolism in hypothyroidism:A positron emission tomography study before and after thyroid hormone replacement therapy. J Clin Endocrinol Metab 94 (8):2922-2929, 2009.
PubMed
16) Biondi B, et al:The clinical significance of subclinical thyroid dysfunction. Endocrine Rev 29 (1):76-131, 2008.
PubMed
17) Parle J, et al:A randomized controlled trial of the effect of thyroxine replacement oncognitive function in community-living elderly subjects with subclinical hypothyroidism:The Birmingham Elderly Thyroid Study. J Clin Endocrinol Metab 95 (8):3623-3632, 2010.
 
18) Gussekloo J, et al:Thyroid status, disability and cognitive function, and survival in oldage. JAMA 292:2591-2599, 2004.
 
19) Haentjens P, et al:Subclinical thyroid dys-function and mortality:an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 159:329-341, 2008.
 
20) Grozinsky-Glasberg S, et al:Thyroxine-tri-iodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism:meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 91:2592-2599, 2006.
 
21) Panicker V, et al:Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 94 (5):1623-1629, 2009.
PubMed
22) Celi F S, et al:Metabolic effects of liothyro-nine therapy in hypothyroidism:A randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab 96 (11):3466-3474, 2011.
 
P.215 掲載の参考文献
1) 百渓尚子, 他:-母体疾患の薬物療法-甲状腺機能異常. 周産期医 39 (11):1551-1557, 2009.
Medical*Online
2) 小澤安則, 他:Subclinical hypothyriodism 潜在性甲状腺機能低下症の診断と治療の手引き (2008年案). ホルモンと臨 56 (7):706-708, 2008.
 
3) 原田正平, 他:阻害型 TSH 受容体抗体による新生児一過性甲状腺機能低下症の出生前診断. ホルモンと臨 38 (11):1129-1133, 1990.
 
4) 日本甲状腺学会:VII 特殊なバセドウ病患者1妊婦・授乳婦. バセドウ病薬物治療のガイドライン 2006 (日本甲状腺学会 編), p117-126. 南江堂, 東京, 2006.
 
5) 原田正平:小児への propylthiouracil 使用について. 内科 107 (1):119-121, 2011.
 
6) 日本甲状腺学会:6 特殊なバセドウ病患者1妊婦・授乳婦. バセドウ病治療ガイドライン 2011 (日本甲状腺学会 編), p123-134. 南江堂, 東京, 2011.
 
7) 荒田尚子:チアマゾールに関連した催奇形性について. 日甲状腺会誌 1 (1):47-50, 2010.
 
8) 日本甲状腺学会:妊娠初期のチアマゾール投与に関する注意喚起について (2011. 11. 30) (http://www.japanthyroid.jp/doctor/information/index.html#ninshin)
 
9) 松浦信夫:TSH レセプター抗体陽性母体より出生する胎児・新生児の甲状腺機能異常. 日甲状腺会誌 1 (1):43-46, 2010.
 
P.224 掲載の参考文献
1) 亀山香織, 他:治療を誤らない細胞診所見と病理診断の読み方. 甲状腺疾患治療マニュアル (高見 博, 他 編), p19-24. 南江堂, 東京, 2002.
 
2) 高見 博:甲状腺腫瘍. 日医会誌特別号 (生涯教育シリーズ59)-内分泌疾患診療マニュァル (高見 博, 他編), p190-193. 日本医師会, 東京, 2002.
 
3) 高見 博, 他:甲状腺・副甲状腺腫に対する低侵襲性外科治療. 慶応医 80 (1):17-21, 2003.
 
4) Cady B, et al:An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104 (6):947-953, 1988.
PubMed
P.233 掲載の参考文献
1) 絹谷清剛:甲状腺癌 131I 内照射療法. 日甲状腺学会誌 1:72-74, 2010.
 
2) Mazzaferri E I, et al:Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428, 1994.
 
3) 日本内分泌外科学会, 日本甲状腺外科学会編:甲状腺腫瘍診療ガイドライン. 金原出版, 東京, 2010.
 
4) McGriff N J, et al:Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34:554-564-2002.
 
5) Suzuki S, et al:Postoperative bone mineral density and metabolism in female differentaiated thyroid carcinoma patients. Thyroidol Clin Exp 10:255-259, 1998.
 
6) Gupta-Abramson V, et al:Phase 11 trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719, 2008.
 
7) Kloos R T, et al:Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684, 2009.
PubMed
8) Hoftijzer H, et al:Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with:differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931, 2009.
 
9) Cohen E E W, et al:Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26:6025, 2008.
 
10) Nemunaitis J J, et al:Phase I dose escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 26:634, 2008.
 
11) Sherman S I, et al:Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42, 2008.
PubMed
12) Gosnell W J, et al:Vandetanib for the treatment of patients with local advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772, 2010.
PubMed
13) deGroot J W, et al:A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endoerinol Metab 92:3466-3469, 2007.
 
14) Pennell N A, et al:A phase II trial of gefidnib in patients with advanced thyroid cancer. Thyroid 18:317-323, 2008.
PubMed
15) Besic N, et al:Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 27:260-264, 2001.
PubMed
16) 鈴木眞一, 他:化学療法のみで著明な改善を示した甲状腺未分化癌長期生存例の1例. 癌の臨床 41:1633-1638, 1995.
 
17) 鈴木眞一:甲状腺未分化癌. 外科治療 96:733-739, 2007.
Medical*Online
18) Higashiyama T, et al:Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20:7-14, 2010.
PubMed
19) 鈴木眞一, 他:甲状腺未分化癌研究コンソーシアム設立の経緯と現状. 内分泌外科 28:2011.
 
20) Sugitani I, et al:Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma:ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36 (6):1247-1254, 2012.
 
21) Pierie J P, et al:The effect of surgery and radiotherapy on:outcome of anaplastic thyroid carcinoma Ann Surg Oncol 9:57-64, 2002.
PubMed
22) 鈴木眞一:甲状腺悪性リンパ腫. 内分泌腺腫瘍-基礎・臨床研究のアップデート, 362-367, 日本臨床, 大阪, 2011.
 
23) 鈴木眞一, 他:Epi-VEP 療法にて完全寛解を得た甲状腺原発悪性リンパ腫の1治験例. 癌の臨床 39:1128-1132, 1993.
Medical*Online
24) Nakhjavani M K, et al:Metastasis to the thyroid gland. Cancer 79:574-578, 1997.
 
25) 大塚健司, 他:転移性甲状腺癌の一例と本邦報告例について. 日気食会報 45:468-477, 1994.
 
26) Lin J D, et al:Clinical and pathological characteristics of secondary thyroid cancer. Thyroid 8:140-153, 1998.
 
27) Horace K I:Cancer metastatic to the thyroid. Mayo Clin Proc 59:856-859, 1984.
 
28) Smith S A, et al:Fine-needle aspiration. Arch lntern Med 147:311-312, 1987.
PubMed
29) Lam K Y, et al:Metastatic tumors of the thyroid gland. Arch Pathol lab Med 122:37-41, 1998.
PubMed
30) Rosen I B, et al:W Secondary malignancy of the thyroid gland and its management Ann Surg Oncol 2:252-256, 1995
 

第5章 放射線障害と甲状腺疾患

P.241 掲載の参考文献
1) Preston D L, et al:Solid cancer incidence in atomic bomb survivors:1958-1998. Radiat Res 168:1-64, 2007.
PubMed
2) Ron E, et al:Thyroid cancer after exposureto external radiation:a pooled analysis of seven studies. Radiat Res 141:259-277, 1995.
 
3) Nagataki S, et al:Thyroid diseases among atomic bomb survivors in Nagasaki. JAMA 272:364-370, 1994.
PubMed
4) Imaizumi M, et al:Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. JAMA 295:1011-1022, 2006.
PubMed
5) Preston D L et al:Solid cancer incidence in atomic bomb survivors exposed in utero or as young children. J Natl Cancer Inst 100:428-436, 2008.
 
6) Imaizumi M, et al:Thyroid diseases in atomic bomb survivors exposed in utero. J Clin Endocrinol Metab 93:1641-1648, 2008.
PubMed
7) Hamatani K, et al:RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res 68:7176-7182, 2008.
PubMed
8) Yoshimoto Y, et al:Prevalence rate of thyroid diseases among autopsy cases of the atomic bomb survivors in Hiroshima, 1951-1985. Radiat Res 141:278-286, 1995.
PubMed
9) Fujiwara S, et al:Autoantibodies and immunoglobulins among atomic bomb survivors. Radiat Res 137:89-95, 1994.
PubMed
P.251 掲載の参考文献
1) Saenko V, et al:The Chernobyl accidents and its consequences. Clin Oncol 23:234-243, 2011.
PubMed
2) Cardis, et al:Risk of thyroid cancer after exposure to 131-I in childhood. J Natl Cancer Inst 97 (10) 724-732, 2005
PubMed
3) Demidchik Y E, et al:Childhood thyroid cancer in Belarus, Russia and Ukraine after Chernobyl and at present. Arq Bras Endocrinol Metabol 51 (5):748-762, 2007.
PubMed
4) Wlliams E D, et al:Thyroid carcinoma after Chernobyl latent period, morphology andaggressiveness. Br J Cancer 90:2219-2224, 2004.
 
5) Williams E D, et al:Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake. Thyroid 18:847-852, 2008.
PubMed
6) Saenko V, et al:Chernobyl thyroid cancer 25 years after:in search of a molecular radiation signature. Hot Thyroidology (www.hotthyroidology.com), HT 8/10, 2010.
 
7) http://www.chernobyltissuebank.com/
 
8) Takahashi M, et al:The FOXEI locus is a major determinant for radiation-related thyroid cancer in Chernobyl. Hum Mol Genet 19 (12):2516-2523, 2010.
 
9) Gudmudsson J, et al:Discovery of common variants associated with low TSH levels and thyroid cancerrisk. Nat Genet 44 (3):319-322, 2012.
 
10) Yamashita S, et al:Mechanisms of Disease. molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab 3 (5):422-429, 2007.
PubMed
11) Suzuki K, et al:Low dose radiation exposure and thyroid carcinogenesis. Jap J Clin Oncol 2012.
 
12) Hayashida N, et al:Screening of 137Cs body burden due to the Chernobyl accidentin Korosten, Zhitomir City, Ukraine;1998-2008. J Radiat Res 52 (5):629-633, 2011.
 
13) IAEA:The Chernobyl Forum; 2003-2005. pp52. 2006.
 
14) http://fukushimamimamori.jp/
 
15) Tokonami S, et al:Thyroid doses for evacuees from the Fukushima nuclear accident. Scientific Report2:507, 1-4, 2012.
 
16) WHO:Preliminary dose estimation from the nuclear accident after the 2011 Great East Japan Earthquake and Tsumami. pp120. 2012.
 
17) Yasumura S, et al:The Fukushima health management survey; study protocol. J Epidemiol 2012 (in press)
 
18) 日本乳腺甲状腺超音波診断会議, 他編:甲状腺超音波診断ガイドブック改訂 第2版. p163. 南光堂, 東京, 2012.
 
19) 鈴木眞一: 特集2 甲状腺放射線障害. チェルノブイリ原発事故を教訓に開始した福島県小児甲状腺超音波検査の現状と展望. 日甲状腺会誌 3 (1):24-29, 2012.
 
20) Ozasa K, et al:Studies of the mortality of atomic bomb survivors, Report 14, 1950-2003;an overview of cancer and noncancer diseases. Radiat Res 177 (3):229-243, 2012.
PubMed
P.260 掲載の参考文献
1) 菊地 央:福島第一原子力発電所での緊急作業に従事した作業員の安定ヨウ素剤内服等について原子力安全委員会 原子力施設等防災専門部会被ばく医療分科会 第30回資料 (http://www.nsc.go.jp/senmon/shidai/hibakubun/hibakubun030/siryo4-3.pdf)
 
2) 原子力安全・保安院:放射性物質放出量データの一部誤りについて 平成23年10月20日 (http://www.meti.go.jp/press/2011/10/20111020001/20111020001.pdf)
 
3) Roberts R M:Serendipity:Accidental discoveries in science. pp31-32. John Wileyand Sons, New York, 1989.
 
4) Institute of Medicine, Food and Nutrition Board:Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. pp258. National Academy Press, Washington DC, 2001.
 
5) Sternthal E, et al:Suppression of thyroid radioiodine uptake by various doses of stable iodide. N Engl J Med 303:1083-1088, 1980.
PubMed
6) Zanzonico P B, et al:Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by 131I from radioactive fallout. Health Phys 78:660-667, 2000.
PubMed
7) Berman M, et al:The routine fitting of kinetic data to models:A mathematical formalism for digital computers. Biophys J2:275-316, 1962.
 
8) Boston R C, et al:Conversational SAAM-an interactive program for kinetic analysis of biological systems. Computer Programs Biomed 13:111-119, 1981.
PubMed
9) Wolff J:Iodide goiter and the pharmacologic effects of excess iodide. Am J Med 47:101-124, 1969.
PubMed
10) Suzuki H, et al:Endemic coast goitre in Hokkaido, Japan. Acta Endocrinol 50:161-176, 1965.
PubMed
11) Namba H, et al:Evidence of thyroid volume increase in normal subjects receiving excess iodide. J Clin Endocrinol Metab 76:605-608, 1993.
PubMed
12) 日本原子力文化振興財団:原子力・エネルギー図面集 2012. 東京.
 

書評

最近チェックした商品履歴

Loading...